Suppr超能文献

抗CD3单克隆抗体加重组白细胞介素-2诱导的人CD4+辅助/杀伤性T细胞的产生、增殖及靶向作用。一种过继性肿瘤免疫治疗的有效策略。

Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.

作者信息

Nishimura T, Nakamura Y, Takeuchi Y, Tokuda Y, Iwasawa M, Kawasaki A, Okumura K, Habu S

机构信息

Department of Immunology, Tokai University School of Medicine, Isehara, Japan.

出版信息

J Immunol. 1992 Jan 1;148(1):285-91.

PMID:1345787
Abstract

We developed a culture system for the rapid generation of CD4+ T cells that have both helper and killer functions. CD4+ T cells isolated from human PBL did not proliferate or develop significant cytotoxicity when treated with rIL-2 because of the lack of p75 IL-2R expression. However, culture of isolated CD4+ T cells with immobilized anti-CD3 mAb plus rIL-2 resulted in a marked proliferation (500-fold increase in 14 days) of CD4+ T cells. The proliferating CD4+ T cells produced IL-2 (92 U/ml) and showed strong cytotoxicity against OKT3 hybridoma cells and Daudi, K562, and U937 tumor cells in an anti-CD3 mAb-dependent manner. The CD4+ T cells contained significant amounts of cytolytic granule-related proteins such as serine esterase and perforin. Activated CD4+ helper/killer cells can be generated from both healthy donors and tumor patients and can be propagated in vitro for 14 to 35 days by biweekly restimulation with immobilized anti-CD3 mAb plus rIL-2. This culture yielded about 20,000-fold increase in cell number after a 21-day culture. Bispecific antibody containing anti-CD3 and anti-glioma Fab components enhanced the cytotoxicity of activated CD4+ helper/killer cells against IMR32 glioma cells. Moreover, the activated CD4+ helper/killer cells showed both helper and antitumor activity in vivo and prevented growth of anti-CD3 hybridoma cells in nude mice whether or not IL-2 was administered. These results indicate that anti-CD3 mAb plus IL-2-activated CD4+ helper/killer cells may provide an effective strategy for adoptive tumor immunotherapy of cancer.

摘要

我们开发了一种用于快速生成兼具辅助和杀伤功能的CD4+ T细胞的培养系统。从人外周血淋巴细胞(PBL)中分离出的CD4+ T细胞,在用重组白细胞介素-2(rIL-2)处理时,由于缺乏p75白细胞介素-2受体(IL-2R)表达,不会增殖或产生显著的细胞毒性。然而,将分离出的CD4+ T细胞与固定化抗CD3单克隆抗体(mAb)加rIL-2一起培养,会导致CD4+ T细胞显著增殖(14天内增加500倍)。增殖的CD4+ T细胞产生白细胞介素-2(92 U/ml),并以抗CD3 mAb依赖的方式对OKT3杂交瘤细胞以及Daudi、K562和U937肿瘤细胞表现出强大的细胞毒性。这些CD4+ T细胞含有大量与溶细胞颗粒相关的蛋白质,如丝氨酸酯酶和穿孔素。活化的CD4+辅助/杀伤细胞可从健康供体和肿瘤患者中产生,并可通过每两周用固定化抗CD3 mAb加rIL-2重新刺激在体外增殖14至35天。经过21天培养,这种培养使细胞数量增加了约20000倍。含有抗CD3和抗胶质瘤Fab片段的双特异性抗体增强了活化的CD4+辅助/杀伤细胞对IMR32胶质瘤细胞的细胞毒性。此外,活化的CD4+辅助/杀伤细胞在体内表现出辅助和抗肿瘤活性,无论是否给予IL-2,均可阻止抗CD3杂交瘤细胞在裸鼠体内生长。这些结果表明,抗CD3 mAb加IL-2活化的CD4+辅助/杀伤细胞可能为癌症的过继性肿瘤免疫治疗提供一种有效的策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验